Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that members of its executive leadership team will present and host investor meetings at several upcoming conferences. **Details on the ...

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme (HALO – Research Report), with a price ...

Analysis of Halozyme Therapeutics, Inc.'s recent developments including revenue growth, patent expiration concerns, and new ...

On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a modest uptick, ending the day at $49 which represents a slight increase of $3.30 or 7.22% from the prior close of $45.7. The stock opened at ...

As the signs point toward a potential Evotec acquisition, delve into what it could represent for the European biotech ...

Halozyme Therapeutics stock is trading -21.53% below its average target price of $62.44 after marking a 7.2% during today's ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

Quest Partners LLC boosted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1,386.0% during ...

Halozyme Therapeutics, a San Diego-based biopharmaceutical company, has made a $2.1 billion bid to buy German drugmaker ...

The local company announced Friday morning at 5:35 a.m. that it was withdrawing its bid to buy Evotec for about $11.52 per ...

Halozyme Therapeutics (HALO) announced it has withdrawn its non-binding proposal to acquire Evotec SE (EVO) for EUR 11.00 per share in cash, ...

Halozyme stock rises after withdrawing its €2B acquisition offer for Evotec, while reaffirming strong growth outlook for 2024 ...